Results 191 to 200 of about 78,778 (305)

Three separate pancreatic acinar cell receptors employ different combinations of intracellular pathways to Ca2+ signalling

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Intracellular pathways leading to Ca2+ signalling in pancreatic acinar cells, initiated by binding of ACh to muscarinic M3 receptors (M3Rs), gastrin‐releasing peptide (GRP) to bombesin type 2 receptors (BB2Rs) or cholecystokinin (CCK) to CCK1 receptors (CCK1Rs). M3R activation produces inositol 1,4,5‐trisphophate (IP3), releasing
Muhanad Salih   +3 more
wiley   +1 more source

Microglial Labeling in Mouse Spinal Cord Injury: A Review of Timing, Efficacy, and Specificity

open access: yesGlia, Volume 74, Issue 12, December 2026.
The transcriptional profile of microglia is significantly altered after spinal cord injury (SCI). When choosing a marker to label microglia after SCI, it is important to consider its specificity for microglia and its stability of expression. ABSTRACT Traumatic spinal cord injury (SCI) is a complex and disabling condition with no curative therapy ...
Ruth Colbert   +2 more
wiley   +1 more source

BCMA Antigen Loss Through Acquired TNFRSF17 Deletion in Multiple Myeloma

open access: yes
International Journal of Laboratory Hematology, EarlyView.
Ali Benaboud   +5 more
wiley   +1 more source

mRNA-dendritic cell antigen vaccine potentiates CD38 CAR-T Cell therapy for relapsed/refractory acute myeloid leukemia. [PDF]

open access: yesTheranostics
Lu Y   +13 more
europepmc   +1 more source

Real‐World Retrospective Analysis of Daratumumab for Relapsed or Refractory Multiple Myeloma in Regional Australia

open access: yesAsia-Pacific Journal of Clinical Oncology, Volume 22, Issue 6, Page 840-843, December 2026.
This retrospective case series evaluated all patients treated with daratumumab between 2018 and 2023 across two regional hospitals in Australia. Fifty‐two patients were included with a median age of 74. Median progression‐free survival (PFS) was 13 months and overall survival (OS) was 27 months, with an overall response rate was 35%.
Benjamin Reardon   +2 more
wiley   +1 more source

Real-world outcomes of CD34⁺ mobilization and early autologous hematopoietic stem cell transplantation recovery after daratumumab-based induction. [PDF]

open access: yesHematol Transfus Cell Ther
Dos Anjos AS   +8 more
europepmc   +1 more source

SKY92 Identifies High‐Risk Newly Diagnosed Multiple Myeloma With Inferior Progression‐Free Survival and Implicates NUF2 as a Candidate Driver

open access: yesEuropean Journal of Haematology, Volume 117, Issue 6, Page 1518-1530, December 2026.
ABSTRACT Objectives To determine the prevalence and prognostic significance of the SKY92 gene‐expression signature, evaluate minimal/measurable residual disease (MRD), and identify molecular drivers of high‐risk disease in transplant‐eligible newly diagnosed multiple myeloma (TE‐NDMM) patients in the Republic of Ireland.
Roisin M. McAvera   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy